Jul 13, 2026 07:30AM
Jul 1, 2026 07:05AM
Jun 24, 2026 07:30AM
Jun 24, 2026 07:30AM
Jun 16, 2026 07:31AM
Jun 16, 2026 07:30AM
Jun 1, 2026 07:30AM Cognition Therapeutics Participating in Upcoming Investor Conferences
May 21, 2026 07:30AM
May 21, 2026 07:30AM
May 14, 2026 07:31AM
May 14, 2026 07:30AM
May 7, 2026 04:15PM
Mar 31, 2026 04:31PM
Mar 31, 2026 04:30PM Cognition Therapeutics CEO Issues Letter to Shareholders
Mar 26, 2026 07:31AM
Mar 26, 2026 07:30AM
Mar 17, 2026 07:31AM
Mar 17, 2026 07:30AM
Mar 2, 2026 07:31AM
Mar 2, 2026 07:30AM
Feb 5, 2026 07:31AM Cognition Therapeutics extends drug access program for dementia patients
Feb 5, 2026 07:30AM
Jan 27, 2026 07:31AM
Jan 27, 2026 07:30AM
Jan 6, 2026 07:30AM
Jan 6, 2026 07:30AM
Dec 3, 2025 07:30AM
Dec 3, 2025 07:30AM Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Dec 1, 2025 07:31AM
Dec 1, 2025 07:30AM
Nov 6, 2025 07:30AM
Aug 12, 2025 04:00PM
Aug 12, 2025 04:00PM
Aug 7, 2025 04:00PM
Jul 29, 2025 07:30AM Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
Jul 21, 2025 07:31AM
Jul 21, 2025 07:30AM
Jul 16, 2025 07:31AM
Jul 16, 2025 07:30AM
Jul 14, 2025 07:07AM
Jul 10, 2025 07:31AM
Jul 10, 2025 07:30AM Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease
Jun 26, 2025 06:45AM
Jun 25, 2025 07:30AM
May 7, 2025 07:30AM
Mar 24, 2025 06:42AM
Mar 20, 2025 07:00AM
Feb 26, 2025 07:00AM
Feb 26, 2025 07:00AM Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy
Jan 8, 2025 04:14PM

326,551 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All